Akut koroner sendromlu hastalarda serum ürik asit / HDL-K oranı ile SYNTAX skoru ile değerlendirilen koroner arter hastalığı kompleksitesi arasındaki ilişki

Yıl 2024, Cilt: 15 Sayı: 4, 562 - 568, 31.12.2024

Emir Derviş , Hasan Can Könte , Mehmet Beşiroğlu

https://doi.org/10.18663/tjcl.1553897

Öz

Amaç: SYNTAX skoru, koroner arter hastalığı (KAH) kompleksitesini değerlendiren önemli bir anjiyografik araç olup, koroner arter bypass greftleme (KABG) ve perkütan koroner girişim (PKG) arasında karar vermede rehberlik eder. Yüksek ürik asit (ÜA) ve düşük yüksek yoğunluklu lipoprotein kolesterol (HDL-K) seviyeleri olumsuz kardiyovasküler olaylarla ilişkilidir. ÜA/ HDL-K oranı (ÜHO), metabolik disregülasyon ve inflamasyonun bir biyobelirteçi olarak önerilmiştir. Bu çalışmanın amacı, akut koroner sendrom (AKS) hastalarında ÜHO ile SYNTAX skoru arasındaki ilişkiyi incelemektir.
Gereç ve Yöntemler: Retrospektif çalışmaya Türkiye’den üç merkezde AKS tanısı alan ve koroner anjiyografi yapılan 536 hasta dahil edilmiştir. Kronik böbrek hastalığı, geçirilmiş PKG/KABG veya statin tedavisi alan hastalar dışlanmıştır. Klinik veriler ve ÜA, HDL-K gibi biyokimyasal parametreler toplandı. SYNTAX skoru çevrimiçi bir hesaplama aracıyla belirlendi. Yüksek SYNTAX skorunun (>22) bağımsız öngördürücülerini belirlemek için çok değişkenli lojistik regresyon analizi yapıldı.
Bulgular: Ortalama SYNTAX skoru 17.60 ± 8.57 bulundu. Diyabetes mellitus (OR: 1.911, p=0.013) ve düşük sol ventrikül ejeksiyon fraksiyonu (LVEF) (OR: 0.951, p<0.001), yüksek SYNTAX skoru ile bağımsız olarak ilişkilendirildi. ÜHO, koroner kompleksite ile anlamlı bir ilişki göstermedi.
Sonuç: Çalışmamızda ÜHO’ nun, AKS hastalarında yüksek SYNTAX skorunu öngörmede etkili bir biyobelirteç olduğu saptanmamıştır. ÜHO' nun metabolik bozukluğu yansıttığı görülse de, bu hasta grubunda koroner kompleksiteyi öngörmek için güvenilir bir biyobelirteç olmayabilir. ÜHO'nun farklı kardiyovasküler durumlarda rolünü araştırmak için daha fazla çalışmaya ihtiyaç vardır.

Anahtar Kelimeler

Ürik asit, HDL kolesterol, koroner arter hastalığı, akut koroner sendrom

The relationship between serum uric acid to HDL-C ratio and the SYNTAX score in patients with acute coronary syndrome

Öz

Aim: The SYNTAX score is an essential angiographic scoring system that evaluates the complexity of coronary artery disease (CAD) and helps guide decision-making between coronary artery bypass graft (CABG) and percutaneous coronary intervention (PCI). Elevated uric acid (UA) and reduced high-density lipoprotein cholesterol (HDL-C) have been linked to adverse cardiovascular events. The UA to HDL-C ratio (UHR) has been proposed as a biomarker for metabolic dysregulation and inflammation. This study aims to investigate the relationship between UHR and SYNTAX score in patients with acute coronary syndrome (ACS).
Material and Methods: This retrospective study included 536 patients with ACS from three hospitals in Turkey, who underwent coronary angiography. Patients with chronic kidney disease, prior PCI/CABG, or on statins were excluded. Clinical data and biochemical parameters, including UA and HDL-C, were collected. The SYNTAX score was calculated using an online tool. Multivariate logistic regression was conducted to determine predictors of a high SYNTAX score (>22).
Results: The mean SYNTAX score was 17.60 ± 8.57. Diabetes mellitus (OR: 1.911, p=0.013) and reduced left ventricular ejection fraction (LVEF) (OR: 0.951, p<0.001) were independently associated with a high SYNTAX score. UHR was not significantly associated with coronary complexity.
Conclusion: UHR was not found to be a predictor for high SYNTAX score in ACS patients. These findings suggest that while UHR may reflect metabolic dysregulation, it may not be a reliable biomarker for coronary complexity in this patient population. Further studies are needed to explore UHR’s role in different cardiovascular settings.

Anahtar Kelimeler

Uric acid, HDL cholesterol, coronary artery disease, acute coronary syndrome

Kaynakça

• Sianos G, Morel M-A, Kappetein AP, et al: The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention 2005, 1(2):219-227.
• Serruys PW, Morice M-C, Kappetein AP, et al: Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. New England journal of medicine 2009, 360(10):961-972.
• Ikeno F, Brooks MM, Nakagawa K, et al: SYNTAX score and long- term outcomes: the BARI-2D trial. Journal of the American College of Cardiology 2017, 69(4):395-403.
• Lim SS, Yang Y-L, Chen S-C, et al: Association of variability in uric acid and future clinical outcomes of patient with coronary artery disease undergoing percutaneous coronary intervention. Atherosclerosis 2020, 297:40-46.
• Braga TT, Foresto-Neto O, Camara NOS: The role of uric acid in inflammasome-mediated kidney injury. Current Opinion in Nephrology and Hypertension 2020, 29(4):423-431.
• Yu W, Cheng J-D: Uric acid and cardiovascular disease: an update from molecular mechanism to clinical perspective. Frontiers in pharmacology 2020, 11:582680.
• Maloberti A, Giannattasio C, Bombelli M, et al: Hyperuricemia and risk of cardiovascular outcomes: the experience of the URRAH (uric acid right for heart health) project. High Blood Pressure & Cardiovascular Prevention 2020, 27:121-128.
• Hajizadeh R, Ghaffari S, Salehi R, Mazani S, Aghavali S: Association of serum uric acid level with mortality and morbidity of patients with acute ST-elevation myocardial infarction. Journal of cardiovascular and thoracic research 2016, 8(2):56.
• von Lueder TG, Girerd N, Atar D, et al: Serum uric acid is associated with mortality and heart failure hospitalizations in patients with complicated myocardial infarction: findings from the High‐Risk Myocardial Infarction Database Initiative. European journal of heart failure 2015, 17(11):1144-1151.
• Gofman JW, Glazier F, Tamplin A, Strisower B, Lalla OD: Lipoproteins, coronary heart disease, and atherosclerosis. Physiological Reviews 1954, 34(3):589-607.
• von Eckardstein A, Nordestgaard BG, Remaley AT, Catapano AL: High-density lipoprotein revisited: biological functions and clinical relevance. European heart journal 2023, 44(16):1394-1407.
• Park B, Jung D-H, Lee Y-J: Predictive value of serum uric acid to HDL cholesterol ratio for incident ischemic heart disease in non- diabetic Koreans. Biomedicines 2022, 10(6):1422.
• Yang Y, Zhang J, Jia L, Su J, Ma M, Lin X: Uric acid to high-density lipoprotein cholesterol ratio predicts adverse cardiovascular events in patients with coronary chronic total occlusion. Nutrition, Metabolism and Cardiovascular Diseases 2023, 33(12):2471-2478.
• Deng F, Jia F, Sun Y, et al: Predictive value of the serum uric acid to high-density lipoprotein cholesterol ratio for culprit plaques in patients with acute coronary syndrome. BMC Cardiovascular Disorders 2024, 24(1):155.
• Li F, Zhao D, Li Q, Lin X, Sun H, Fan Q: Uric acid to high-density lipoprotein cholesterol ratio is a novel marker to predict functionally significant coronary artery stenosis. Journal of Interventional Cardiology 2022, 2022.
• Aktas G, Khalid A, Kurtkulagi O, et al: Poorly controlled hypertension is associated with elevated serum uric acid to HDL- cholesterol ratio: a cross-sectional cohort study. Postgraduate medicine 2022, 134(3):297-302.
• Liu R, Peng Y, Wu H, et al: Uric acid to high-density lipoprotein cholesterol ratio predicts cardiovascular mortality in patients on peritoneal dialysis. Nutrition, Metabolism and Cardiovascular Diseases 2021, 31(2):561-569.
• Li X, Meng X, He Y, et al: Genetically determined serum urate levels and cardiovascular and other diseases in UK Biobank cohort: A phenome-wide mendelian randomization study. PLoS medicine 2019, 16(10):e1002937.
• Kobayashi N, Hata N, Tsurumi M, et al: Relation of coronary culprit lesion morphology determined by optical coherence tomography and cardiac outcomes to serum uric acid levels in patients with acute coronary syndrome. The American Journal of Cardiology 2018, 122(1):17-25.
• Mandurino-Mirizzi A, Cornara S, Somaschini A, et al: Elevated serum uric acid is associated with a greater inflammatory response and with short-and long-term mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Nutrition, Metabolism and Cardiovascular Diseases 2021, 31(2):608-614.
• Li M, Hu X, Fan Y, et al: Hyperuricemia and the risk for coronary heart disease morbidity and mortality a systematic review and dose-response meta-analysis. Scientific reports 2016, 6(1):19520. 22. Tai S, Li X, Zhu Z, et al: Hyperuricemia is a risk factor for one‐year overall survival in elderly female patients with acute coronary syndrome. Cardiovascular therapeutics 2020, 2020(1):2615147.
• Julve J, Escolà-Gil JC: High-Density Lipoproteins and Cardiovascular Disease: The Good, the Bad and the Future. In., vol. 9: MDPI; 2021: 857.
• Hu J, Xi D, Zhao J, et al: High-density lipoprotein and inflammation and its significance to atherosclerosis. The American journal of the medical sciences 2016, 352(4):408-415.
• Sorrentino SA, Besler C, Rohrer L, et al: Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended- release niacin therapy. Circulation 2010, 121(1):110-122.
• Park JS, Cha KS, Lee HW, et al: Predictive and protective role of high-density lipoprotein cholesterol in acute myocardial infarction. Cardiology Journal 2019, 26(2):176-185.
• Yang Y, Zhang J, Jia L, Su J, Ma M, Lin X: The interaction between uric acid and high-density lipoprotein cholesterol on the prognosis of patients with acute myocardial infarction. Frontiers in Cardiovascular Medicine 2023, 10:1226108.
• Tseng WC, Chen YT, Ou SM, Shih CJ, Tarng DC: U‐shaped association between serum uric acid levels with cardiovascular and all‐cause mortality in the elderly: the role of malnourishment. Journal of the American Heart Association 2018, 7(4):e007523.
• Güleç S, Erol C: High-density lipoprotein cholesterol and risk of cardiovascular disease. J Cardiol Pract 2020, 19:133-134.
• Hewing B, Moore KJ, Fisher EA: HDL and cardiovascular risk: time to call the plumber? Circulation research 2012, 111(9):1117-1120.
• Franczyk B, Rysz J, Ławiński J, Rysz-Górzyńska M, Gluba-Brzózka A: Is a high HDL-cholesterol level always beneficial? Biomedicines 2021, 9(9):1083.